Read more about the work of Belfast ECMC

  • Belfast ECMC has recently set up a trial of a new anti-angiogenic agent, ALM201, discovered at Queen’s University, Belfast. The first-in-man study in up to 60 patients with ovarian cancer will be run across the ECMC Network. ALM201 was developed into a drug in collaboration with Almac Discovery, a local biotechnology company.

 

  • Belfast ECMC is leading on the pan-European MErCuRIC project involving 13 partners from eight different European countries. This multicentre phase Ib/II clinical trial will assess the combination of a MEK inhibitor with a MET inhibitor to combat metastasis, improve survival and change current clinical practice for colorectal cancer patients with KRAS mutant and wild type tumours. Next generation sequencing and ‘xenopatients’ will be used to identify patient subgroups that will gain maximum benefit from this novel treatment strategy.